Clinical trials: Psychotic Disorder
Schizophrenia, Schizoaffective Disorder
Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.
- Trial name
- NCT00588731
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Yale University
Schizophrenia
Trial of D-Cycloserine in Schizophrenia
To characterize further the effects of D-cycloserine augmentation of antipsychotic treatment on negative symptoms, performance on neurocognitive tasks, and on markers for glutamatergic, dopaminergic and serotonergic function in…
- Trial name
- NCT00000371
- Testing
- D-cycloserine
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Schizophreniform Disorder
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831
This study will evaluate the long-term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder
- Conditions
- Schizophrenia, Schizophreniform Disorder, Bipolar I Disorder
- Trial name
- NCT03201757
- Testing
- ALKS 3831
- Where
- 85 sites in United States, Austria and 11 more
- Volunteers
- 523 people
- Sponsor
- Alkermes, Inc.
Schizophrenia, Schizo Affective Disorder
Models of Auditory Hallucination
The purpose of this study is to address the shortcoming in clinical hallucination research by causally manipulating the neural loci of conditioned hallucination task behavior in-person in patients with psychosis using…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Auditory Hallucination
- Trial name
- NCT04210557
- Testing
- Transcranial Magnetic Stimulation (TMS)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Yale University
Psychosis, Substance Abuse
Effect Evaluation of Individual Placement and Support (IPS)
Roughly one third of disability pensions issued in Norway are classified as mental and behavioral disorders. The proposed study aims to evaluate the effect of an innovative intervention for returning people with moderate to…
- Conditions
- Psychosis, Substance Abuse, Depression, Anxiety
- Trial name
- NCT01964092
- Testing
- Individual Placement and Support, Ordinary employment schemes
- Where
- Norway
- Volunteers
- 410 people
- Sponsor
- NORCE Norwegian Research Centre AS
Schizophrenia
CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia
This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning.
- Trial name
- NCT04860830
- Testing
- Iclepertin
- Where
- 110 sites in United States, Argentina and 16 more
- Volunteers
- 609 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia
Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia
This study will evaluate the effectiveness of galantamine and CDP-choline in improving symptoms associated with schizophrenia.
- Trial name
- STAR-1 (NCT00509067)
- Testing
- Galantamine, CDP-choline, risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Georgetown University
Schizophrenia
Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine
Olanzapine is one of the most effective and best tolerated of the atypical antipsychotics, but it is also particularly associated with weight gain and metabolic problems.
- Trial name
- GWMD09126 (NCT01491490)
- Testing
- GWP42003 : GWP42004 (40:1)
- Where
- 6 sites in United Kingdom
- Volunteers
- 2 people
- Sponsor
- GW Research Ltd
Epilepsy, Schizophrenia
Targeted Self-Management for Epilepsy and Serious Mental Illness (TIME)
For this project we propose to refine the psychosocial intervention developed in phase one, based on input from key stakeholders, and to test the feasibility, acceptability and preliminary efficacy of the intervention.
- Conditions
- Epilepsy, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT01992393
- Testing
- TIME
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Case Western Reserve University
Inflammatory Bowel Diseases, Depressive Episode
Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health
This study is a large population-based analysis in the United Kingdom (UK) using routine primary care data to investigate the impacts on quality-of-life outcomes and use of healthcare services in people aged 5 - 25 years…
- Conditions
- Inflammatory Bowel Diseases, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorder
- Trial name
- NCT05206734
- Testing
- No specific intervention
- Where
- United Kingdom
- Volunteers
- 19,469 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Cannabis Dependence, Marijuana Dependence
Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia
Cannabis use disorders are an important public health problem in the United States, but no effective pharmacotherapies are available to treat these disorders.
- Trial name
- DCCS (NCT01598896)
- Testing
- Dronabinol, Clonidine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mclean Hospital
Schizophrenia
A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia
The purpose of this study is to determine whether luvadaxistat is superior to placebo in improving cerebellar function as measured with the average percentage of conditioned responses during the eyeblink conditioning (EBC) test.
- Trial name
- NCT03359785
- Testing
- Luvadaxistat
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Neurocrine Biosciences
Schizophrenia
Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia
Cognitive training is moderately effective at reducing symptoms and improving life function in schizophrenia patients. The present application develops a strategy for increasing the effectiveness of cognitive training through the…
- Trial name
- Swerdlow-R34 (NCT01555697)
- Testing
- Memantine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of California, San Diego
Schizophrenia, Schizoaffective Disorder
Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia
The goals of this study are to study MMFS-202-302 in a double blind, randomized, placebo-controlled 9-week study of its effect on ameliorating cognitive deficits in 60 patients with schizophrenia or schizoaffective disorder with…
- Trial name
- NCT02237235
- Testing
- MMFS-202-302
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Northwestern University
Schizophrenia
Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients
Schizophrenia is a devastating and costly illness. One-third to one-half of people with schizophrenia do not respond to the most current drugs leaving clozapine as the best alternative for treatment.
- Trial name
- NCT01433055
- Testing
- Minocycline
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia
To assess the effectiveness of aripiprazole once-monthly in the maintenance treatment of patients with a diagnosis of schizophrenia as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text…
- Trial name
- NCT01795547
- Testing
- Aripiprazole and aripiprazole once-monthly, Paliperidone and paliperidone palmitate
- Where
- 2 sites in United States
- Volunteers
- 295 people
- Sponsor
- H. Lundbeck A/S
Cognition in Schizophrenia
Study of the Effects of Mecamylamine and Varenicline in Schizophrenia
We are conducting this study to find out if blocking or partially stimulating the effects of nicotine in the brain can affect memory and concentration. Nicotine is the addictive drug found in tobacco products.
- Trial name
- NCT00455650
- Testing
- Mecamylamine, Varenicline
- Where
- United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Schizoaffective Disorder
Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia
Patients with schizophrenia have problems in thinking, known as cognitive dysfunction. This appears to be responsible for their difficulties in social and occupational functioning.
- Trial name
- NCT00423943
- Testing
- modafinil
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Schizoaffective Disorder, Schizophrenia
Long-Acting Injectable Risperidone in the Treatment of Schizophrenia
In the proposed study 450 veterans with a primary diagnosis of schizophrenia who had at least one psychiatric hospitalization for schizophrenia in the previous 2 years would be randomly assigned at 16 VA medical centers to…
- Trial name
- NCT00132314
- Testing
- IM risperidone, oral antipsychotic medication
- Where
- 19 sites in United States
- Volunteers
- 382 people
- Sponsor
- US Department of Veterans Affairs
Schizophrenia
Safety and Tolerability of BI 409306 in Patients With Schizophrenia
The primary objective of the current study is to investigate the safety and tolerability of BI 409306 in schizophrenic patients following oral administration of multiple low, medium, and high doses over 14 days.
- Trial name
- NCT01892384
- Testing
- BI 409306
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Boehringer Ingelheim